

Press Release

Stockholm, Sweden, September 2, 2024

Mendus to participate in upcoming industry conferences in September

Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will participate in the following upcoming industry and investor conferences in September:

International Society for Cell & Gene Therapy Europe 2024 Regional Meeting

Gothenburg, Sweden, September 4-6, 2024

Mendus will present the regulatory milestones of its clinical-stage programs vididencel and ilixadencel during a poster session held on September 4, 18.30–20.00 CEST. In addition, Mendus Head of Regulatory Affairs, Dr Anna Koptina Gültekin, will participate in a panel discussion held on September 5 about the importance of interactions with regulatory authorities during drug development.

[ISCT EU 2024](#)

H.C. Wainwright 26th Annual Global Investment Conference

New York City, USA, September 9-11

Mendus CEO Erik Manting will participate for investor meetings and a company presentation.

[HCW Events](#)

Nordic Life Science Days 2024

Malmö, Sweden, September 18-19, 2024

Mendus CEO Erik Manting will take part in a presentation hosted by the Dutch Government about the collaboration potential between Sweden and The Netherlands in the Life Sciences sector.

[NLSDays](#)

Pareto Securities' 15th Annual Healthcare Conference

Stockholm, Sweden, September 19, 2024

Mendus CEO Erik Manting will participate for investor meetings and a company presentation.

[Pareto Securities' 15th Annual Healthcare Conference](#)

For more information, please contact:

Erik Manting

Chief Executive Officer

E-mail: ir@mendus.com

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>